emtriva emtricitabine 200mg capsule blister pack
gilead sciences pty ltd - emtricitabine, quantity: 200 mg - capsule, hard - excipient ingredients: crospovidone; povidone; microcrystalline cellulose; magnesium stearate; propylene glycol; purified water; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; potable water; gelatin; sodium lauryl sulfate - emtriva is indicated for the treatment of hiv in combination with other antiretroviral agents in adults and paediatric patients 12 years of age and older, weighing more than 33 kg. evidence to support this claim is based on surrogate markers (plasma hiv rna and cd4 count) in antiretroviral naive individuals and in antiretroviral experienced individuals with virological suppression (see clinical trials).
emtriva emtricitabine 200mg capsule bottle
gilead sciences pty ltd - emtricitabine, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; povidone; crospovidone; titanium dioxide; indigo carmine; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; purified water; ethanol; strong ammonia solution; potassium hydroxide; iron oxide black - emtriva is indicated for the treatment of hiv in combination with other antiretroviral agents in adults and paediatric patients 12 years of age and older, weighing more than 33 kg. evidence to support this claim is based on surrogate markers (plasma hiv rna and cd4 count) in antiretroviral naive individuals and in antiretroviral experienced individuals with virological suppression (see clinical trials).
viread tenofovir disoproxil fumarate 300mg tablet bottle
gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; triacetin - viread in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.,viread is indicated for the treatment of chronic hepatitis b in adults (see clinical trials).,viread is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e. active viral replication, persistently elevated serum alt levels or evidence of active inflammation. viread in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults. viread is indicated for the treatment of chronic hepatitis b in adults with evidence of active viral replication and active liver inflammation.
atripla 300 mg tenofovir disoproxil fumarate/200 mg emtricitabine/600 mg efavirenz tablets bottle
gilead sciences pty ltd - efavirenz,emtricitabine,tenofovir disoproxil fumarate -
sovaldi sofosbuvir 400 mg tablet bottle
gilead sciences pty ltd - sofosbuvir -
epclusa sofosbuvir 400 mg / velpatasvir 100 mg tablet bottle
gilead sciences pty ltd - velpatasvir, quantity: 100 mg; sofosbuvir, quantity: 400 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; copovidone; silicified microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 4000; polyvinyl alcohol - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection (genotype 1, 2, 3, 4, 5 or 6) in adults and paediatric patients 12 years of age and older and weighing 30 kg or more.,(see 4.2 dose and method of administration section for the recommended regimens for different patient subgroups).
harvoni ledipasvir/sofosbuvir 90 mg/400 mg tablet bottle
gilead sciences pty ltd - sofosbuvir, quantity: 400 mg; ledipasvir acetone solvate, quantity: 95.9 mg (equivalent: ledipasvir, qty 90 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; silicon dioxide; magnesium stearate; croscarmellose sodium; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; polyvinyl alcohol; macrogol 3350 - harvoni (ledipasvir/sofosbuvir fixed-dose combination) is indicated for the treatment of chronic hepatitis c (chc) infection in adults. (see precautions and clinical trials sections for information on the available data for hcv patients of each genotype, see dosage and administration section for recommended regimens and treatment durations for different patient subgroups).
cayston aztreonam 75 mg for inhalation vial with diluent ampoule
gilead sciences pty ltd - aztreonam -
cellular therapies
gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; sodium chloride; dimethyl sulfoxide - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large b-cell lymphoma after two or more lines of systemic therapy, including diffuse large b-cell lymphoma (dlbcl) not otherwise specified, primary mediastinal large b-cell lymphoma, high grade b-cell lymphoma, and dlbcl arising from follicular lymphoma. yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
cellular therapies
gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; dimethyl sulfoxide; sodium chloride - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (mcl), who have received two or more lines of therapy, including a btk inhibitor, unless ineligible or intolerant to treatment with a btk inhibitor.